Clinical Results of Combined Systemic Steroid and Retroorbital Radiotherapy Treatment in Active Thyroid Associated Ophthalmopathy-Reference-Cited by-同舟云学术

Clinical Results of Combined Systemic Steroid and Retroorbital Radiotherapy Treatment in Active Thyroid Associated Ophthalmopathy

Published:2023-06-12 Issue:2 Volume:50 Page:149-155
ISSN:1300-2945
Container-title:Dicle Tıp Dergisi
language:
Short-container-title:

Author:

BATU OTO Bilge¹,COLPAN OKSUZ Didem¹,SERT Seda²,UZEL Omer Erol¹,SARİCİ Ahmet Murat¹

Affiliation:

1. ISTANBUL UNIVERSITY-CERRAHPASA, CERRAHPAŞA SCHOOL OF MEDICINE, DEPARTMENT OF BASIC MEDICAL SCIENCES

2. GUMUSHANE UNIVERSITY, GÜMÜŞHANE VOCATIONAL SCHOOL

Abstract

Objective: The aim of this study is to evaluate the efficacy of a different steroid dosage protocol which consists of intravenous pulse methylprednisolone combined with retroorbital radiotherapy in the treatment of active thyroid associated ophthalmopathy. Methods: The medical records of 29 patients who were treated with a standard protocol and who were followed-up for at least 6 months were retrospectively analyzed. The treatment protocol consisted of intravenous pulse methylprednisolone 1gram/day for 3 consecutive days, followed by retroorbital radiotherapy. Oral prednisolone which was tapered over a 3-month course was given as a maintenance dose. Results: 58 eyes of 29 patients were included in the study. Twelve patients were female (41%) and 17 were male (59%) with a mean age of 47.7 ± 12.6 years. The clinical activity score was 4.8 ± 1.3 and 2.8 ± 1.2, before and after treatment, respectively (P

Publisher

Dicle Medical Journal/Dicle Tip Dergisi

Subject

General Earth and Planetary Sciences,General Engineering,General Environmental Science

Reference29 articles.

1. 1.Ginsberg J. Diagnosis and management of Graves'disease. CMAJ. 2003 Mar 4;168(5):575-85.

2. 2.Bahn RS. Graves' ophthalmopathy. N Engl J Med.2010 Feb 25;362(8):726-38. doi: 10.1056/NEJMra0905750.

3. 3.Bartalena L, Tanda ML, Bogazzi F, et al. An update onthe pharmacological management of hyperthyroidismdue to Graves' disease. Expert Opin Pharmacother.2005 Jun;6(6):851-61. doi:10.1517/14656566.6.6.851.

4. 4.Marcocci C, Bartalena L, Bogazzi F, Panicucci M,Pinchera A. Studies on the occurrence ofophthalmopathy in Graves' disease. Acta Endocrinol(Copenh). 1989 Apr;120(4):473-8. doi:10.1530/acta.0.1200473.

5. 5.Bartalena L, Pinchera A, Marcocci C. Management ofGraves' ophthalmopathy: reality and perspectives.Endocr Rev. 2000 Apr;21(2):168-99. doi:10.1210/edrv.21.2.0393.